2014
Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms
KISSOVÁ, Jarmila; Alena BULIKOVÁ; Petra OVESNÁ; Ludmila BOURKOVÁ; Miroslav PENKA et al.Základní údaje
Originální název
Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms
Autoři
Vydání
International Journal of Hematology, Tokio, Springer Japan, 2014, 0925-5710
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30200 3.2 Clinical medicine
Stát vydavatele
Japonsko
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 1.918
Označené pro přenos do RIV
Ano
Kód RIV
RIV/00216224:14110/14:00077527
Organizační jednotka
Lékařská fakulta
UT WoS
EID Scopus
Klíčová slova anglicky
Mean platelet volume (MPV); Immature platelet fraction (IPF); BCR/ABL-negative myeloproliferative neoplasms (MPN); Thrombosis
Štítky
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 24. 4. 2015 13:56, Soňa Böhmová
Anotace
V originále
BCR/ABL-negative myeloproliferative neo¬plasms (MPNs) are considered to be acquired thrombo-philic conditions. Persistently enhanced platelet activation has been described in polycythaemia vera and essential thrombocythaemia (ET), and shown to contribute to a higher risk of arterial and venous thrombotic complica-tions. Recent studies have shown that mean platelet volume (MPV) and immature platelet fraction (1PF) can serve as useful markers of platelet activation and increased risk of thrombosis. The aim of the present study was to investigate the relationship between these parameters and thrombotic events in BCR/ABL-negative MPN. MPV values in patients with BCR/ABL-negative MPN were significantly higher than MPV values of healthy individuals (P < 0.001). No significant difference in MPV or IPF was observed between groups of patients with and without thrombotic complications (P = 0.441; P = 0.110); the difference in IPF values was close to the significance level for patients with ET (P = 0.073). Higher values of IPF were more frequently detected in patients with JAK2 V617F positivity (P = 0.030). These patients had higher MPV more frequently than others, and this difference was close to the significance level (P — 0.056). Further studies should validate the use of platelet parameters to identify patients at high risk.